BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong, M. Philco, Yamil Alonso Lopez Chuken, Marie‐Paule Sablin, Kenji Tamura, Armando Villanueva, José Alejandro Pérez Fidalgo, S.Y. Amy Cheung,

Annals of Oncology